Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
Balance Sheet
Inspect the capital base behind the business.
Assets
$194.78M
FY 2025 · Annual
Liabilities
$371.42M
FY 2025 · Annual
Equity
-$176.63M
FY 2025 · Annual
Balance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $237.4M |
| Short-term Investments | $220.1M |
| Other Current | $6.5M |
| Total Current Assets | $464.0M |
| PP&E (Net) | $1.5M |
| Other Non-current | $2.3M |
| Total Non-current Assets | $3.8M |
| Total Assets | $467.8M |
Analysis
Selected assets total $467.8M for Latest. The largest visible component is Cash & Equivalents at $237.4M, about 50.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 25, 2026 |
How much cash does COAG have?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) reported $87.97M in cash and equivalents in fiscal 2025.
How much debt does COAG carry?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) reported $1.22M of total debt, with net debt of -$86.75M.
Continue the stock analysis
Jump to another research area for this company.